Tide Medicine (03880.HK) Profit Warning: Expected adjusted net profit for 2025 to increase by 16.3% to 33.7% year-on-year

NightAirdropper · 2026-02-26T01:54:30+00:00

Tide Pharmaceuticals expects revenue to increase to approximately 555 million to 585 million yuan by 2025, with profits rising to about 200 million to 230 million yuan. This growth is primarily driven by successful strategic implementation and operational optimization. Adjusted net profit is expected to increase to approximately 200 million to 230 million yuan.

NightAirdropper

2026-02-26 01:54:30

Abstract generation in progress

GKHL February 26 — TIDE MEDICINE (03880.HK) announced that it expects (i) the group’s revenue for the fiscal year ending December 31, 2025, to be approximately RMB 555 million to RMB 585 million, representing an increase of about 25.5% to 32.3% compared to RMB 442.2 million in 2024; (ii) the group’s profit for 2025 to be approximately RMB 200 million to RMB 230 million, up about 237.8% to 288.5% from RMB 59.2 million in 2024; and (iii) the group’s adjusted net profit (non-International Financial Reporting Standards measure) for 2025 to be approximately RMB 200 million to RMB 230 million, an increase of about 16.3% to 33.7% from RMB 172 million in 2024.

The board believes that: (a) revenue growth is mainly due to (i) the successful implementation of the “Follow Molecule” strategy, the advantages of the group’s integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform, industry-leading project delivery timeliness, and excellent project execution track record; and (ii) sustained strong demand from key clients for the group’s services, driven by the advancement of its R&D pipeline and the rapid expansion of the global peptide market (especially in the GLP-1 field); (b) profit growth is primarily due to the combined effects of: (i) the aforementioned revenue increase; (ii) cost savings and efficiency improvements achieved through optimization of the group’s operational management system; and (iii) the fair value gain on financial liabilities recognized at fair value in profit or loss for 2025, due to the redemption of debt when the company’s H-shares listed on the Stock Exchange of Hong Kong converted into equity, whereas in 2024, a fair value loss was recorded; and © the increase in adjusted net profit is mainly due to (i) the aforementioned revenue growth, and (ii) the combined effect of cost savings and efficiency improvements from optimizing the group’s operational management system.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes